

Candidiasis Therapeutics Market 2026

<https://marketpublishers.com/r/C0199C73D659EN.html>

Date: November 2025

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: C0199C73D659EN

Abstracts

The Candidiasis Therapeutics Market was valued at in and is anticipated to reach by , at a CAGR of 0.053 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Candidiasis Therapeutics Market.

This report delivers a comprehensive overview of the Candidiasis Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Candidiasis Therapeutics Market. The Candidiasis Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Candidiasis Therapeutics Market Scope:

Major Highlights

This report delivers a comprehensive overview of the Candidiasis Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Candidiasis Therapeutics Market. The Candidiasis Therapeutics Market size, estimates, and forecasts are

provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. GLOBAL CANDIDIASIS THERAPEUTICS MARKET METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - MARKET DEFINITION AND OVERVIEW

3. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - EXECUTIVE SUMMARY

- 3.1. Market Snippet by Type
- 3.2. Market Snippet by Drug Class
- 3.3. Market Snippet by Route of Administration
- 3.4. Market Snippet by Distribution Channel
- 3.5. Market Snippet by Region

4. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - MARKET DYNAMICS

- 4.1. Market Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing number of patients affected by candidiasis infection
 - 4.1.1.2. Growing awareness of candidiasis infection
 - 4.1.1.3. XX
 - 4.1.2. Restraints:
 - 4.1.2.1. Availability of alternative treatments
 - 4.1.2.2. Side-effects caused by the drugs
 - 4.1.2.3. XX
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - INDUSTRY ANALYSIS

- 5.1. Epidemiology
- 5.2. Pipeline Analysis
- 5.3. Porter's Five Forces Analysis
- 5.4. Supply Chain Analysis

- 5.5. Clinical Trials
- 5.6. Pricing Analysis
- 5.7. Regulatory Analysis
- 5.8. Reimbursement Analysis
- 5.9. Unmet Needs

6. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - COVID-19 ANALYSIS

- 6.1. Analysis of Covid-19 on the Market
 - 6.1.1. Before COVID-19 Market Scenario
 - 6.1.2. Present COVID-19 Market Scenario
 - 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion

7. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
 - 7.1.2. Market Attractiveness Index, By Type Segment
- 7.2. Oral Candidiasis*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
- 7.3. Vulvovaginal Candidiasis
- 7.4. Cutaneous Candidiasis
- 7.5. Invasive Candidiasis
- 7.6. Systemic Candidiasis

8. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY DRUG CLASS

- 8.1. Introduction
 - 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 8.1.2. Market Attractiveness Index, By Drug Class Segment
- 8.2. Polyene*
 - 8.2.1. Introduction

8.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028

8.2.3. Nystatin (Mycostatin and others)

8.2.4. Amphotericin B (Fungizone, Amphocin)

8.3. Azole Antifungals

8.3.1. Fluconazole (Diflucan)

8.3.2. Itraconazole (Sporanox)

8.3.3. Voriconazole (Vfend)

8.3.4. Posaconazole (Noxafil)

8.4. Topical azoles

8.4.1. Clotrimazole (Mycelex, Femizole-7)

8.4.2. Butoconazole (Femstat-3, Gynazole-1)

8.4.3. Miconazole vaginal (Monistat, Micatin)

8.4.4. Tioconazole (Vagistat-1)

8.4.5. Terconazole vaginal (Terazol-7, Terazol-3)

8.5. Glucan synthesis inhibitors (echinocandins)

8.5.1. Caspofungin (Cancidas)

8.5.2. Micafungin (Mycamine)

8.5.3. Anidulafungin (Eraxis)

8.6. Antimetabolite

8.6.1. Flucytosine (Ancobon)

8.7. Allylamines

8.7.1. Terbinafine (Daskil, Lamisil)

8.8. Others

9. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY ROUTE OF ADMINISTRATION

9.1. Introduction

9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment

9.1.2. Market Attractiveness Index, By Route of Administration Segment

9.2. Oral*

9.2.1. Introduction

9.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028

9.3. Parenteral

9.4. Topical

10. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY DISTRIBUTION CHANNEL

10.1. Introduction

10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment

10.1.2. Market Attractiveness Index, By Distribution Channel Segment

10.2. Hospital Pharmacies*

10.2.1. Introduction

10.2.2. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028

10.3. Online Pharmacies

10.4. Retail Pharmacies

10.5. Others

11. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - BY REGION

11.1. Introduction

11.1.1. Market Size Analysis, US\$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region

11.1.2. Market Attractiveness Index, By Region

11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.2.7.1. The U.S.

11.2.7.2. Canada

11.2.7.3. Mexico

11.3. Europe

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of

Administration

11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.3.7.1. Germany

11.3.7.2. The U.K.

11.3.7.3. France

11.3.7.4. Italy

11.3.7.5. Spain

11.3.7.6. Rest of Europe

11.4. South America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of

Administration

11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.4.7.1. Brazil

11.4.7.2. Argentina

11.4.7.3. Rest of South America

11.5. Asia Pacific

11.5.1. Introduction

11.5.2. Key Region-Specific Dynamics

11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of

Administration

11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.5.7.1. China

11.5.7.2. India

11.5.7.3. Japan

11.5.7.4. Australia

11.5.7.5. Rest of Asia Pacific

11.6. Middle East and Africa

11.6.1. Introduction

11.6.2. Key Region-Specific Dynamics

11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type

- 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - COMPETITIVE LANDSCAPE

- 12.1. Key Developments and Strategies
- 12.2. Company Share Analysis
- 12.3. Product Benchmarking
- 12.4. List of key companies to watch
- 12.5. List of the company with disruptive technology
- 12.6. List of start-up companies

13. GLOBAL CANDIDIASIS THERAPEUTICS MARKET- COMPANY PROFILES

- 13.1. Cidara Therapeutics Inc.*
 - 13.1.1. Company Overview
 - 13.1.2. Product Portfolio and Description
 - 13.1.3. Key Highlights
 - 13.1.4. Financial Overview
- 13.2. NovaDigm Therapeutics Inc
- 13.3. Amplyx Pharmaceuticals Inc.
- 13.4. Astellas Pharma Inc.
- 13.5. Basilea Pharmaceutica Ltd.
- 13.6. Grupo Ferrer Internacional, S.A.
- 13.7. Pacgen Biopharmaceuticals
- 13.8. Viamet Pharmaceuticals Holdings, LLC
- 13.9. Mycovia Pharmaceuticals Inc
- 13.10. Novabiotics Limited
- 13.11. Bayer AG
- 13.12. Biomar Microbial Technologies
- 13.13. Merck
- 13.14. Scynexis Inc.
- 13.15. Pfizer, Inc. (*LIST NOT EXHAUSTIVE)

14. GLOBAL CANDIDIASIS THERAPEUTICS MARKET - DATAM

- 14.1. Appendix
- 14.2. About Us and Services
- 14.3. Contact Us

I would like to order

Product name: Candidiasis Therapeutics Market 2026

Product link: <https://marketpublishers.com/r/C0199C73D659EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C0199C73D659EN.html>